Drug Research
Lilly and UnitedHealth Group partner on pragmatic study of neutralizing antibody bamlanivimab for COVID-19
Eli Lilly and Company and UnitedHealth Group announced a partnership to conduct a pragmatic study of bamlanivimab (LY-CoV555) in high-risk, COVID-19 infected individuals.
Bamlanivimab recently received EUA by the U.S. FDA for the treatment of mild to moderate COVID-19 patients...
Drug Research
Rush For A COVID Vaccine- Is It Science Or Politics…?
COVID-19 vaccine usage announcement by the UK has brought us to the brink where other countries too might jump on the bandwagon. Is it safe or are we rushing into things? We only hope that science triumphs over politics.
Are...
News
Samsung Biologics drives digital transformation with Plant 4 Virtual Showroom launch
Samsung Biologics announced the launch of a virtual showroom to provide key features and real-time construction updates of its recently announced Plant 4. The digital showcase also highlights various specs and services that the Super Plant will offer upon...
News
Gerresheimer: Syringes for Biotechnologically Manufactured Active Ingredients
Biotechnologically manufactured active ingredients demonstrate a series of special features. Some are highly viscous, concentrated and in individual cases, tend to interact with silicone oil or, for example, tungsten residue from syringe production. Gerresheimer Biologcial Solutions offers a special...
News
Pfizer, Moderna & AstraZeneca – Pricing, Storage and Efficacy Comparison
Pfizer COVID-19 vaccine doses to be stored around -70 degrees celsius and will cost around $20 a dose.
Moderna vaccine to cost around $25 a dose and can remain stable at -20 degree celsius.
AstraZeneca will cost $2.50...
Drug Research
Batavia and KU Leuven join forces to accelerate development of highly promising COVID-19 vaccine candidate
KU Leuven, a leading research institution and one of the top 50 universities in the world and Batavia Biosciences, a contract development and manufacturing organization focused on delivering sustainable manufacturing solutions in the field of vaccines and oncology, announce...
News
Ufovax extends IP portfolio to include patent covering the design of an optimized antigen for COVID-19
Ufovax, a vaccine biotechnology company, has extended its intellectual property portfolio to include an exclusive global license to a patent covering the design of an optimized antigen for SARS-CoV-2 (“COVID-19”). The patent, entitled Stabilized Coronavirus Spike (S) Protein Immunogens...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
















